ABSTRACT
The use of immunohistochemistry in the reporting of prostate biopsies is an important adjunct when the diagnosis is not definite on haematoxylin and eosin (H&E) morphology alone. The process is however inherently inefficient with delays while waiting for pathologist review to make the request and duplicated effort reviewing a case more than once. In this study, we aimed to capture the workflow implications of immunohistochemistry requests and demonstrate a novel artificial intelligence tool to identify cases in which immunohistochemistry (IHC) is required and generate an automated request.
We conducted audits of the workflow for prostate biopsies in order to understand the potential implications of automated immunohistochemistry requesting and collected prospective cases to train a deep neural network algorithm to detect tissue regions that presented ambiguous morphology on whole slide images. These ambiguous foci were selected on the basis of the pathologist requesting immunohistochemistry to aid diagnosis. A gradient boosted trees classifier was then used to make a slide level prediction based on the outputs of the neural network prediction. The algorithm was trained on annotations of 219 immunohistochemistry-requested and 80 control images, and tested by 3-fold cross- validation. Validation was conducted on a separate validation dataset of 212 images.
Non IHC-requested cases were diagnosed in 17.9 minutes on average, while IHC-requested cases took 33.4 minutes over multiple reporting sessions. We estimated 11 minutes could be saved on average per case by automated IHC requesting, by removing duplication of effort. The tool attained 99% accuracy and 0.99 Area Under the Curve (AUC) on the test data. In the validation, the average agreement with pathologists was 0.81, with a mean AUC of 0.80.
We demonstrate the proof-of-principle that an AI tool making automated immunohistochemistry requests could create a significantly leaner workflow and result in pathologist time savings.
Competing Interest Statement
PathLAKE has received in-kind industry investment from Philips. Oxford University and Oxford University Hospitals NHS Foundation Trust are part of the PathLAKE consortium. JR, KS and AA are co-founders of Ground Truth Labs.
Funding Statement
This paper is supported by the PathLAKE Centre of Excellence for digital pathology and artificial intelligence which is funded from the Data to Early Diagnosis and Precision Medicine strand of the HM Government Industrial Strategy Challenge Fund, managed and delivered by Innovate UK on behalf of UK Research and Innovation (UKRI). Views expressed are those of the authors and not necessarily those of the PathLAKE Consortium members, the NHS, Innovate UK or UKRI. Grant ref: File Ref 104689 / application number 18181. AC is funded by the Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Council (MRC), grant number EP/L016052/1. CV and LB are part funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted under the PathLAKE research ethics committee approval (South Central Oxford C Research Ethics Committee (UK), reference 19/SC/0363) and consent to data research was checked. Patients are not identifiable from the material. The research was performed in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† PathLAKE Principal Investigator
COMPETING INTERESTS STATEMENT: JR, KS and AA are co-founders of Ground Truth Labs. PathLAKE has received in kind industry investment from Philips. University of Oxford and Oxford University Hospitals NHS Foundation Trust are part of the PathLAKE consortium.
Data Availability
The datasets generated during and/or analysed during the current study are not publicly available due to the terms of the PathLAKE Consortium Agreement but are available via the corresponding author on reasonable request.
